DOCSLIB.ORG

NARG1 (NAA15) (NM 057175) Human Tagged ORF Clone Product Data

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
NARG1 (NAA15) (NM 057175) Human Tagged ORF Clone Product Data OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for RC210884 NARG1 (NAA15) (NM_057175) Human Tagged ORF Clone Product data: Product Type: Expression Plasmids Product Name: NARG1 (NAA15) (NM_057175) Human Tagged ORF Clone Tag: Myc-DDK Symbol: NAA15 Synonyms: Ga19; MRD50; NARG1; NAT1P; NATH; TBDN; TBDN100 Vector: pCMV6-Entry (PS100001) E. coli Selection: Kanamycin (25 ug/mL) Cell Selection: Neomycin This product is to be used for laboratory only. Not for diagnostic or therapeutic use. View online » ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 1 / 4 NARG1 (NAA15) (NM_057175) Human Tagged ORF Clone – RC210884 ORF Nucleotide >RC210884 representing NM_057175 Sequence: Red=Cloning site Blue=ORF Green=Tags(s) TTTTGTAATACGACTCACTATAGGGCGGCCGGGAATTCGTCGACTGGATCCGGTACCGAGGAGATCTGCC GCCGCGATCGCC ATGCCGGCCGTGAGCCTCCCGCCCAAGGAGAATGCGCTCTTCAAGCGGATCTTGAGGTGTTATGAACATA AACAGTATAGAAATGGATTGAAATTCTGTAAACAAATACTTTCTAATCCCAAATTTGCAGAGCATGGAGA AACCTTGGCTATGAAAGGATTAACATTGAACTGTTTGGGGAAAAAGGAAGAAGCTTATGAATTGGTTCGT AGAGGTTTGAGAAATGACTTGAAGAGTCATGTGTGTTGGCACGTTTATGGCCTTCTTCAGAGGTCAGACA AGAAGTATGATGAAGCCATTAAGTGTTACAGAAATGCACTAAAATGGGATAAAGACAATCTTCAAATCTT AAGGGACCTTTCCTTACTACAGATTCAAATGCGAGATCTTGAGGGTTACAGGGAAACGAGGTATCAGTTA CTTCAGCTTCGACCTGCGCAGAGAGCATCATGGATTGGTTATGCTATTGCTTACCATTTATTAGAAGATT ATGAAATGGCAGCAAAGATTTTAGAAGAATTTAGGAAAACACAACAGACATCCCCTGACAAGGTGGATTA TGAATATAGTGAACTACTCTTATATCAGAATCAAGTTCTTCGGGAAGCAGGTCTCTATAGAGAAGCTTTG GAACATCTTTGTACCTATGAAAAGCAGATTTGTGATAAACTTGCTGTAGAAGAAACCAAAGGGGAACTTC TGTTGCAACTATGTCGTTTGGAAGATGCTGCAGATGTTTATAGAGGATTGCAAGAGAGAAATCCTGAAAA CTGGGCCTATTACAAAGGCTTGGAAAAAGCACTCAAGCCAGCTAATATGTTAGAACGGCTAAAAATTTAT GAGGAAGCCTGGACTAAATATCCCAGGGGACTGGTGCCAAGAAGGCTGCCGTTAAACTTTTTATCTGGTG AGAAGTTTAAAGAATGTTTGGATAAGTTCCTAAGGATGAATTTCAGCAAGGGTTGCCCACCAGTCTTCAA TACTTTAAGATCATTATACAAAGACAAAGAAAAGGTGGCAATCATAGAAGAGTTAGTAGTAGGTTATGAA ACCTCTCTAAAAAGCTGCCGGTTATTTAACCCCAATGATGATGGAAAGGAGGAACCACCAACCACATTAC TTTGGGTCCAGTACTACTTGGCACAACATTATGACAAAATTGGTCAGCCATCTATTGCTTTGGAGTACAT AAATACTGCTATTGAAAGTACACCTACATTAATAGAACTCTTTCTCGTGAAAGCTAAAATCTATAAGCAT GCTGGAAATATTAAAGAAGCTGCAAGGTGGATGGATGAGGCCCAGGCCTTGGACACAGCAGACAGATTTA TCAACTCCAAATGTGCAAAATACATGCTAAAAGCCAACCTGATTAAAGAAGCTGAAGAAATGTGCTCAAA GTTTACAAGGGAAGGAACATCAGCGGTAGAGAATTTGAATGAAATGCAGTGCATGTGGTTCCAAACAGAA TGTGCCCAGGCTTATAAAGCAATGAATAAATTTGGTGAAGCACTTAAGAAATGTCATGAGATTGAGAGAC ATTTTATAGAAATCACTGATGACCAGTTTGACTTTCATACATACTGTATGAGGAAGATTACCCTTAGATC ATATGTGGACTTATTAAAACTAGAAGATGTACTTCGACAGCATCCATTTTACTTCAAGGCAGCAAGAATT GCTATAGAGATCTATTTGAAGCTTCATGACAACCCCCTTACAGATGAGAATAAAGAACACGAAGCTGATA CAGCAAACATGTCTGACAAAGAGCTAAAGAAGCTACGTAATAAACAAAGAAGAGCTCAAAAGAAAGCCCA GATAGAAGAAGAGAAAAAAAATGCAGAAAAAGAAAAGCAGCAGAGAAATCAGAAAAAGAAGAAGGATGAT GATGATGAGGAGATAGGAGGTCCAAAAGAAGAACTTATTCCAGAGAAACTGGCCAAGGTTGAAACTCCAT TGGAAGAAGCTATTAAATTTTTAACACCGTTGAAGAACTTGGTGAAGAACAAGATAGAGACTCATCTTTT TGCCTTTGAGATTTACTTTAGGAAAGAAAAGTTTCTTTTGATGCTACAATCAGTAAAGAGGGCATTTGCT ATTGATTCTAGTCATCCCTGGCTTCATGAGTGTATGATTCGTCTCTTTAATACTGCAGTGTGTGAAAGTA AAGATTTATCTGATACAGTTAGAACAGTATTAAAACAAGAAATGAATCGTCTTTTTGGAGCAACGAATCC AAAGAATTTTAATGAAACTTTTCTGAAAAGGAATTCTGATTCATTGCCACACAGATTATCAGCTGCCAAA ATGGTATATTACTTAGATCCTTCTAGTCAGAAGCGAGCTATAGAGTTGGCAACAACACTTGATGAATCTC TCACTAACAGAAACCTCCAGACATGTATGGAGGTATTGGAAGCCTTGTATGATGGTAGCCTAGGAGACTG TAAAGAAGCTGCTGAAATTTATAGAGCAAATTGTCATAAGCTTTTCCCTTATGCTTTGGCTTTCATGCCT CCTGGATATGAAGAGGATATGAAGATCACAGTTAATGGAGATAGTTCTGCAGAAGCTGAAGAACTGGCCA ATGAAATT ACGCGTACGCGGCCGCTCGAGCAGAAACTCATCTCAGAAGAGGATCTGGCAGCAAATGATATCCTGGATT ACAAGGATGACGACGATAAGGTTTAA This product is to be used for laboratory only. Not for diagnostic or therapeutic use. ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 2 / 4 NARG1 (NAA15) (NM_057175) Human Tagged ORF Clone – RC210884 Protein Sequence: >RC210884 representing NM_057175 Red=Cloning site Green=Tags(s) MPAVSLPPKENALFKRILRCYEHKQYRNGLKFCKQILSNPKFAEHGETLAMKGLTLNCLGKKEEAYELVR RGLRNDLKSHVCWHVYGLLQRSDKKYDEAIKCYRNALKWDKDNLQILRDLSLLQIQMRDLEGYRETRYQL LQLRPAQRASWIGYAIAYHLLEDYEMAAKILEEFRKTQQTSPDKVDYEYSELLLYQNQVLREAGLYREAL EHLCTYEKQICDKLAVEETKGELLLQLCRLEDAADVYRGLQERNPENWAYYKGLEKALKPANMLERLKIY EEAWTKYPRGLVPRRLPLNFLSGEKFKECLDKFLRMNFSKGCPPVFNTLRSLYKDKEKVAIIEELVVGYE TSLKSCRLFNPNDDGKEEPPTTLLWVQYYLAQHYDKIGQPSIALEYINTAIESTPTLIELFLVKAKIYKH AGNIKEAARWMDEAQALDTADRFINSKCAKYMLKANLIKEAEEMCSKFTREGTSAVENLNEMQCMWFQTE CAQAYKAMNKFGEALKKCHEIERHFIEITDDQFDFHTYCMRKITLRSYVDLLKLEDVLRQHPFYFKAARI AIEIYLKLHDNPLTDENKEHEADTANMSDKELKKLRNKQRRAQKKAQIEEEKKNAEKEKQQRNQKKKKDD DDEEIGGPKEELIPEKLAKVETPLEEAIKFLTPLKNLVKNKIETHLFAFEIYFRKEKFLLMLQSVKRAFA IDSSHPWLHECMIRLFNTAVCESKDLSDTVRTVLKQEMNRLFGATNPKNFNETFLKRNSDSLPHRLSAAK MVYYLDPSSQKRAIELATTLDESLTNRNLQTCMEVLEALYDGSLGDCKEAAEIYRANCHKLFPYALAFMP PGYEEDMKITVNGDSSAEAEELANEI TRTRPLEQKLISEEDLAANDILDYKDDDDKV Chromatograms: https://cdn.origene.com/chromatograms/mk8114_f04.zip Restriction Sites: SgfI-MluI Cloning Scheme: This product is to be used for laboratory only. Not for diagnostic or therapeutic use. ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 3 / 4 NARG1 (NAA15) (NM_057175) Human Tagged ORF Clone – RC210884 Plasmid Map: ACCN: NM_057175 ORF Size: 2598 bp OTI Disclaimer: The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. More info OTI Annotation: This clone was engineered to express the complete ORF with an expression tag. Expression varies depending on the nature of the gene. RefSeq: NM_057175.5 RefSeq Size: 5554 bp RefSeq ORF: 2601 bp Locus ID: 80155 UniProt ID: Q9BXJ9, B2RBE5 Domains: TPR Protein Families: Druggable Genome, Transcription Factors MW: 101.1 kDa Gene Summary: N-alpha-acetylation is among the most common post-translational protein modifications in eukaryotic cells. This process involves the transfer of an acetyl group from acetyl-coenzyme A to the alpha-amino group on a nascent polypeptide and is essential for normal cell function. This gene encodes the auxillary subunit of the N-terminal acetyltransferase A (NatA) complex. [provided by RefSeq, Jan 2017] This product is to be used for laboratory only. Not for diagnostic or therapeutic use. ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 4 / 4.
Load more

Recommended publications
  • Supp Material.Pdf
    Simon et al. Supplementary information: Table of contents p.1 Supplementary material and methods p.2-4 • PoIy(I)-poly(C) Treatment • Flow Cytometry and Immunohistochemistry • Western Blotting • Quantitative RT-PCR • Fluorescence In Situ Hybridization • RNA-Seq • Exome capture • Sequencing Supplementary Figures and Tables Suppl. items Description pages Figure 1 Inactivation of Ezh2 affects normal thymocyte development 5 Figure 2 Ezh2 mouse leukemias express cell surface T cell receptor 6 Figure 3 Expression of EZH2 and Hox genes in T-ALL 7 Figure 4 Additional mutation et deletion of chromatin modifiers in T-ALL 8 Figure 5 PRC2 expression and activity in human lymphoproliferative disease 9 Figure 6 PRC2 regulatory network (String analysis) 10 Table 1 Primers and probes for detection of PRC2 genes 11 Table 2 Patient and T-ALL characteristics 12 Table 3 Statistics of RNA and DNA sequencing 13 Table 4 Mutations found in human T-ALLs (see Fig. 3D and Suppl. Fig. 4) 14 Table 5 SNP populations in analyzed human T-ALL samples 15 Table 6 List of altered genes in T-ALL for DAVID analysis 20 Table 7 List of David functional clusters 31 Table 8 List of acquired SNP tested in normal non leukemic DNA 32 1 Simon et al. Supplementary Material and Methods PoIy(I)-poly(C) Treatment. pIpC (GE Healthcare Lifesciences) was dissolved in endotoxin-free D-PBS (Gibco) at a concentration of 2 mg/ml. Mice received four consecutive injections of 150 μg pIpC every other day. The day of the last pIpC injection was designated as day 0 of experiment.
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • From Stem Cells to Populations—Using Hipsc, Next-Generation Sequencing, and GWAS to Explore the Genetic and Molecular Mechanisms of Congenital Heart Defects
    G C A T T A C G G C A T genes Review From Stem Cells to Populations—Using hiPSC, Next-Generation Sequencing, and GWAS to Explore the Genetic and Molecular Mechanisms of Congenital Heart Defects Martin Broberg 1,2, Johanna Hästbacka 3 and Emmi Helle 1,4,* 1 Stem Cells and Metabolism Research Program, Faculty of Medicine, University of Helsinki, 00290 Helsinki, Finland; martin.broberg@helsinki.fi 2 Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, 00290 Helsinki, Finland 3 New Children’s Hospital, and Pediatric Research Center, Department of Anesthesia and Intensive Care, Helsinki University Hospital, 00290 Helsinki, Finland; johanna.r.hastbacka@hus.fi 4 New Children’s Hospital, and Pediatric Research Center, Department of Pediatrics, Helsinki University Hospital, 00290 Helsinki, Finland * Correspondence: emmi.helle@helsinki.fi Abstract: Congenital heart defects (CHD) are developmental malformations affecting the heart and the great vessels. Early heart development requires temporally regulated crosstalk between multiple cell types, signaling pathways, and mechanical forces of early blood flow. While both genetic and en- vironmental factors have been recognized to be involved, identifying causal genes in non-syndromic CHD has been difficult. While variants following Mendelian inheritance have been identified by linkage analysis in a few families with multiple affected members, the inheritance pattern in most Citation: Broberg, M.; Hästbacka, J.; familial cases is complex, with reduced penetrance and variable expressivity. Furthermore, most Helle, E. From Stem Cells to non-syndromic CHD are sporadic. Improved sequencing technologies and large biobank collections Populations—Using hiPSC, Next-Generation Sequencing, and have enabled genome-wide association studies (GWAS) in non-syndromic CHD.
    [Show full text]
  • Truncating Variants in NAA15 Are Associated with Variable Levels of Intellectual Disability, Autism Spectrum Disorder, and Congenital Anomalies
    Manuscript Truncating variants in NAA15 are associated with variable levels of intellectual disability, autism spectrum disorder, and congenital anomalies Authors: Hanyin Cheng1*, Avinash V. Dharmadhikari1*, Sylvia Varland2,44, Ning Ma3,4,5, Deepti Domingo6, Robert Kleyner7, Alan F. Rope8, Margaret Yoon7, Asbjørg Stray-Pedersen9,10, Jennifer E. Posey9, Sarah R. Crews11, Mohammad K. Eldomery9, Zeynep Coban Akdemir9, Andrea M. Lewis9,12, Vernon R. Sutton9, Jill A. Rosenfeld9, Erin Conboy13, Katherine Agre13, Fan Xia1,9, Magdalena Walkiewicz1,9,14, Mauro Longoni15,16, Frances A. High15,17,18, Marjon A. van Slegtenhorst19, Grazia M.S. Mancini19, Candice R. Finnila20, Arie van Haeringen21, Nicolette den Hollander21, Claudia Ruivenkamp21, Sakkubai Naidu22, Sonal Mahida22, Elizabeth E. Palmer23,24, Lucinda Murray23, Derek Lim25, Parul Jayakar26, Michael J. Parker27, Stefania Giusto28, Eman- uela Stracuzzi28, Corrado Romano28, Jennifer S. Beighley29, Raphael A. Bernier29, Sébastien Küry30, Mathilde Nizon30, Mark A. Corbett31, Marie Shaw31, Alison Gardner31, Christopher Barnett32, Ruth Armstrong33, Karin S. Kassahn34,35, Anke Van Dijck36, Geert Vandew- eyer36,Tjitske Kleefstra37, Jolanda Schieving37, Marjolijn J. Jongmans37, Bert B.A. de Vries37, Rolph Pfundt37, Bronwyn Kerr38, Samantha K. Rojas39, Kym M. Boycott39, Richard Person40, Re- becca Willaert40, Evan E. Eichler41,42, R. Frank Kooy36, Yaping Yang1,9, Joseph C. Wu3,4,5, James R. Lupski9,43, Thomas Arnesen2,44,45, Gregory M. Cooper20, Wendy K. Chung46, Jozef Gecz6,31,47, Holly A.F. Stessman11,**, Linyan Meng1,9,**, Gholson J. Lyon7,** 1. Baylor Genetics, Houston, TX, 77021, USA; 2. Department of Biomedicine, University of Bergen, N-5020 Bergen, Norway; 3. Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA; 4.
    [Show full text]
  • Initiation of Antiviral B Cell Immunity Relies on Innate Signals from Spatially Positioned NKT Cells
    Initiation of Antiviral B Cell Immunity Relies on Innate Signals from Spatially Positioned NKT Cells The MIT Faculty has made this article openly available. Please share how this access benefits you. Your story matters. Citation Gaya, Mauro et al. “Initiation of Antiviral B Cell Immunity Relies on Innate Signals from Spatially Positioned NKT Cells.” Cell 172, 3 (January 2018): 517–533 © 2017 The Author(s) As Published http://dx.doi.org/10.1016/j.cell.2017.11.036 Publisher Elsevier Version Final published version Citable link http://hdl.handle.net/1721.1/113555 Terms of Use Creative Commons Attribution 4.0 International License Detailed Terms http://creativecommons.org/licenses/by/4.0/ Article Initiation of Antiviral B Cell Immunity Relies on Innate Signals from Spatially Positioned NKT Cells Graphical Abstract Authors Mauro Gaya, Patricia Barral, Marianne Burbage, ..., Andreas Bruckbauer, Jessica Strid, Facundo D. Batista Correspondence [email protected] (M.G.), [email protected] (F.D.B.) In Brief NKT cells are required for the initial formation of germinal centers and production of effective neutralizing antibody responses against viruses. Highlights d NKT cells promote B cell immunity upon viral infection d NKT cells are primed by lymph-node-resident macrophages d NKT cells produce early IL-4 wave at the follicular borders d Early IL-4 wave is required for efficient seeding of germinal centers Gaya et al., 2018, Cell 172, 517–533 January 25, 2018 ª 2017 The Authors. Published by Elsevier Inc. https://doi.org/10.1016/j.cell.2017.11.036 Article Initiation of Antiviral B Cell Immunity Relies on Innate Signals from Spatially Positioned NKT Cells Mauro Gaya,1,2,* Patricia Barral,2,3 Marianne Burbage,2 Shweta Aggarwal,2 Beatriz Montaner,2 Andrew Warren Navia,1,4,5 Malika Aid,6 Carlson Tsui,2 Paula Maldonado,2 Usha Nair,1 Khader Ghneim,7 Padraic G.
    [Show full text]
  • This Item Is the Archived Peer-Reviewed Author-Version Of
    This item is the archived peer-reviewed author-version of: Targeted sequencing identifies 91 neurodevelopmental-disorder risk genes with autism and developmental-disability biases Reference: Stessman Holly A. F., Xiong Bo, Coe Bradley P., Wang Tianyun, Hoekzema Kendra, Fenckova Michaela, Kvarnung Malin, Gerdts Jennifer, Trinh Sandy, Cosemans Nele, ....- Targeted sequencing identifies 91 neurodevelopmental-disorder risk genes with autism and developmental-disability biases Nature genetics - ISSN 1061-4036 - 49:4(2017), p. 515-526 Full text (Publisher's DOI): http://dx.doi.org/doi:10.1038/NG.3792 To cite this reference: http://hdl.handle.net/10067/1424230151162165141 Institutional repository IRUA 1 Targeted sequencing identifies 91 neurodevelopmental disorder risk genes with autism 2 and developmental disability biases 3 4 Holly A. F. Stessman1,Ψ,α, Bo Xiong1,2,Ψ, Bradley P. Coe1,β, Tianyun Wang3,β, Kendra 5 Hoekzema1, Michaela Fenckova4,5, Malin Kvarnung6,7, Jennifer Gerdts8, Sandy Trinh8, Nele 6 Cosemans9, Laura Vives1, Janice Lin1, Tychele N. Turner1, Gijs Santen10, Claudia 7 Ruivenkamp10, Marjolein Kriek10, Arie van Haeringen10, Emmelien Aten10, Kathryn Friend11,12, 8 Jan Liebelt13, Christopher Barnett13, Eric Haan11,13, Marie Shaw11, Jozef Gecz11,14, Britt-Marie 9 Anderlid6,7, Ann Nordgren6,7, Anna Lindstrand6,7, Charles Schwartz15, R. Frank Kooy16, Geert 10 Vandeweyer16, Celine Helsmoortel16, Corrado Romano17, Antonino Alberti17, Mirella Vinci17, 11 Emanuela Avola17, Stefania Giusto18, Eric Courchesne19, Tiziano Pramparo19, Karen Pierce19, 12 Srinivasa Nalabolu19, David Amaral20, Ingrid E. Scheffer21,22,23, Martin B. Delatycki21,24,25, Paul J. 13 Lockhart21,25, Fereydoun Hormozdiari26, Benjamin Harich4,5, Anna Castells-Nobau4,5, Kun Xia3, 14 Hilde Peeters9, Magnus Nordenskjöld6,7, Annette Schenck4,5, Raphael A.
    [Show full text]
  • Understanding the Genetic Basis of Phenotype Variability in Individuals with Neurocognitive Disorders
    Understanding the genetic basis of phenotype variability in individuals with neurocognitive disorders Michael H. Duyzend A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy University of Washington 2016 Reading Committee: Evan E. Eichler, Chair Raphael Bernier Philip Green Program Authorized to Offer Degree: Genome Sciences 1 ©Copyright 2016 Michael H. Duyzend 2 University of Washington Abstract Understanding the genetic basis of phenotype variability in individuals with neurocognitive disorders Michael H. Duyzend Chair of the Supervisory Committee: Professor Evan E. Eichler Department of Genome Sciences Individuals with a diagnosis of a neurocognitive disorder, such as an autism spectrum disorder (ASD), can present with a wide range of phenotypes. Some have severe language and cognitive deficiencies while others are only deficient in social functioning. Sequencing studies have revealed extreme locus heterogeneity underlying the ASDs. Even cases with a known pathogenic variant, such as the 16p11.2 CNV, can be associated with phenotypic heterogeneity. In this thesis, I test the hypothesis that phenotypic heterogeneity observed in populations with a known pathogenic variant, such as the 16p11.2 CNV as well as that associated with the ASDs in general, is due to additional genetic factors. I analyze the phenotypic and genotypic characteristics of over 120 families where at least one individual carries the 16p11.2 CNV, as well as a cohort of over 40 families with high functioning autism and/or intellectual disability. In the 16p11.2 cohort, I assessed variation both internal to and external to the CNV critical region. Among de novo cases, I found a strong maternal bias for the origin of deletions (59/66, 89.4% of cases, p=2.38x10-11), the strongest such effect so far observed for a CNV associated with a microdeletion syndrome, a significant maternal transmission bias for secondary deletions (32 maternal versus 14 paternal, p=1.14x10-2), and nine probands carrying additional CNVs disrupting autism-associated genes.
    [Show full text]
  • Agricultural University of Athens
    ΓΕΩΠΟΝΙΚΟ ΠΑΝΕΠΙΣΤΗΜΙΟ ΑΘΗΝΩΝ ΣΧΟΛΗ ΕΠΙΣΤΗΜΩΝ ΤΩΝ ΖΩΩΝ ΤΜΗΜΑ ΕΠΙΣΤΗΜΗΣ ΖΩΙΚΗΣ ΠΑΡΑΓΩΓΗΣ ΕΡΓΑΣΤΗΡΙΟ ΓΕΝΙΚΗΣ ΚΑΙ ΕΙΔΙΚΗΣ ΖΩΟΤΕΧΝΙΑΣ ΔΙΔΑΚΤΟΡΙΚΗ ΔΙΑΤΡΙΒΗ Εντοπισμός γονιδιωματικών περιοχών και δικτύων γονιδίων που επηρεάζουν παραγωγικές και αναπαραγωγικές ιδιότητες σε πληθυσμούς κρεοπαραγωγικών ορνιθίων ΕΙΡΗΝΗ Κ. ΤΑΡΣΑΝΗ ΕΠΙΒΛΕΠΩΝ ΚΑΘΗΓΗΤΗΣ: ΑΝΤΩΝΙΟΣ ΚΟΜΙΝΑΚΗΣ ΑΘΗΝΑ 2020 ΔΙΔΑΚΤΟΡΙΚΗ ΔΙΑΤΡΙΒΗ Εντοπισμός γονιδιωματικών περιοχών και δικτύων γονιδίων που επηρεάζουν παραγωγικές και αναπαραγωγικές ιδιότητες σε πληθυσμούς κρεοπαραγωγικών ορνιθίων Genome-wide association analysis and gene network analysis for (re)production traits in commercial broilers ΕΙΡΗΝΗ Κ. ΤΑΡΣΑΝΗ ΕΠΙΒΛΕΠΩΝ ΚΑΘΗΓΗΤΗΣ: ΑΝΤΩΝΙΟΣ ΚΟΜΙΝΑΚΗΣ Τριμελής Επιτροπή: Aντώνιος Κομινάκης (Αν. Καθ. ΓΠΑ) Ανδρέας Κράνης (Eρευν. B, Παν. Εδιμβούργου) Αριάδνη Χάγερ (Επ. Καθ. ΓΠΑ) Επταμελής εξεταστική επιτροπή: Aντώνιος Κομινάκης (Αν. Καθ. ΓΠΑ) Ανδρέας Κράνης (Eρευν. B, Παν. Εδιμβούργου) Αριάδνη Χάγερ (Επ. Καθ. ΓΠΑ) Πηνελόπη Μπεμπέλη (Καθ. ΓΠΑ) Δημήτριος Βλαχάκης (Επ. Καθ. ΓΠΑ) Ευάγγελος Ζωίδης (Επ.Καθ. ΓΠΑ) Γεώργιος Θεοδώρου (Επ.Καθ. ΓΠΑ) 2 Εντοπισμός γονιδιωματικών περιοχών και δικτύων γονιδίων που επηρεάζουν παραγωγικές και αναπαραγωγικές ιδιότητες σε πληθυσμούς κρεοπαραγωγικών ορνιθίων Περίληψη Σκοπός της παρούσας διδακτορικής διατριβής ήταν ο εντοπισμός γενετικών δεικτών και υποψηφίων γονιδίων που εμπλέκονται στο γενετικό έλεγχο δύο τυπικών πολυγονιδιακών ιδιοτήτων σε κρεοπαραγωγικά ορνίθια. Μία ιδιότητα σχετίζεται με την ανάπτυξη (σωματικό βάρος στις 35 ημέρες, ΣΒ) και η άλλη με την αναπαραγωγική
    [Show full text]
  • Autocrine IFN Signaling Inducing Profibrotic Fibroblast Responses By
    Downloaded from http://www.jimmunol.org/ by guest on September 23, 2021 Inducing is online at: average * The Journal of Immunology , 11 of which you can access for free at: 2013; 191:2956-2966; Prepublished online 16 from submission to initial decision 4 weeks from acceptance to publication August 2013; doi: 10.4049/jimmunol.1300376 http://www.jimmunol.org/content/191/6/2956 A Synthetic TLR3 Ligand Mitigates Profibrotic Fibroblast Responses by Autocrine IFN Signaling Feng Fang, Kohtaro Ooka, Xiaoyong Sun, Ruchi Shah, Swati Bhattacharyya, Jun Wei and John Varga J Immunol cites 49 articles Submit online. Every submission reviewed by practicing scientists ? is published twice each month by Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://jimmunol.org/subscription Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html http://www.jimmunol.org/content/suppl/2013/08/20/jimmunol.130037 6.DC1 This article http://www.jimmunol.org/content/191/6/2956.full#ref-list-1 Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* Why • • • Material References Permissions Email Alerts Subscription Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2013 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. This information is current as of September 23, 2021. The Journal of Immunology A Synthetic TLR3 Ligand Mitigates Profibrotic Fibroblast Responses by Inducing Autocrine IFN Signaling Feng Fang,* Kohtaro Ooka,* Xiaoyong Sun,† Ruchi Shah,* Swati Bhattacharyya,* Jun Wei,* and John Varga* Activation of TLR3 by exogenous microbial ligands or endogenous injury-associated ligands leads to production of type I IFN.
    [Show full text]
  • Investigating the Functionality of a Ribosome-Binding Mutant of NAA15
    Varland and Arnesen BMC Res Notes (2018) 11:404 https://doi.org/10.1186/s13104-018-3513-4 BMC Research Notes RESEARCH NOTE Open Access Investigating the functionality of a ribosome‑binding mutant of NAA15 using Saccharomyces cerevisiae Sylvia Varland1,2,3* and Thomas Arnesen1,2,4 Abstract Objective: N-terminal acetylation is a common protein modifcation that occurs preferentially co-translationally as the substrate N-terminus is emerging from the ribosome. The major N-terminal acetyltransferase complex A (NatA) is estimated to N-terminally acetylate more than 40% of the human proteome. To form a functional NatA complex the catalytic subunit NAA10 must bind the auxiliary subunit NAA15, which properly folds NAA10 for correct substrate acetylation as well as anchors the entire complex to the ribosome. Mutations in these two genes are associated with various neurodevelopmental disorders in humans. The aim of this study was to investigate the in vivo functionality of a Schizosaccharomyces pombe NAA15 mutant that is known to prevent NatA from associating with ribosomes, but retains NatA-specifc activity in vitro. Results: Here, we show that Schizosaccharomyces pombe NatA can functionally replace Saccharomyces cerevisiae NatA. We further demonstrate that the NatA ribosome-binding mutant Naa15 ΔN K6E is unable to rescue the temper- ature-sensitive growth phenotype of budding yeast lacking NatA. This fnding indicates the in vivo importance of the co-translational nature of NatA-mediated N-terminal acetylation. Keywords: N-terminal acetyltransferase, NatA, NAA10, NAA15, N-terminal acetylation, Ribosome association, Saccharomyces cerevisiae Introduction acetyltransferases (NATs). Te biological importance of N-terminal acetylation is one of the most common this protein modifcation is underscored by the fact that protein modifcations in eukaryotes, occurring on dysfunctional NATs are implicated in a variety of devel- approximately 80–90% of all human proteins [1–3].
    [Show full text]
  • Supplementary Information
    SUPPLEMENTARY INFORMATION 1. SUPPLEMENTARY FIGURE LEGENDS Supplementary Figure 1. Long-term exposure to sorafenib increases the expression of progenitor cell-like features. A) mRNA expression levels of PROM-1 (CD133), THY-1 (CD90), EpCAM, KRT19, and VIM assessed by quantitative real-time PCR. Data represent the mean expression value for a gene in each phenotypic type of cells, displayed as fold-changes normalized to 1 (expression value of its corresponding parental non-treated cell line). Expression level is relative to the GAPDH gene. Bars indicate standard deviation. Significant statistical differences are set at p<0.05. B) Immunocitochemical staining of CD90 and vimentin in Hep3B sorafenib resistant cell line and its parental cell line. C) Western blot analysis comparing protein levels in resistant Hu6 and Hep3B cells vs their corresponding parental cells lines. Supplementary Figure 2. Efficacy of gene silencing of IGF1R and FGFR1 and evaluation of MAPK14 signaling activation. IGF1R and FGFR1 knockdown expression 48h after transient transfection with siRNAs (50 nM), in non-treated parental cells and sorafenib-acquired resistant tumor derived cells was assessed by quantitative RT-PCR (A) and western blot (B). C) Activation status of MAPK14 signaling was evaluated by western blot analysis in vivo, in tumors with acquired resistance to sorafenib in comparison to non-treated tumors (right panel), as well as in in vitro, in sorafenib resistant cell lines vs parental non-treated. Supplementary Figure 3. Gene expression levels of several pro-angiogenic factors. mRNA expression levels of FGF1, FGF2, VEGFA, IL8, ANGPT2, KDR, FGFR3, FGFR4 assessed by quantitative real-time PCR in tumors harvested from mice.
    [Show full text]
  • Prospective Lncrna-Mirna-Mrna Regulatory
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 40: 1895-1906, 2017 Prospective lncRNA-miRNA-mRNA regulatory network of long non-coding RNA LINC00968 in non-small cell lung cancer A549 cells: A miRNA microarray and bioinformatics investigation DONG-YAO LI1*, WEN-JIE CHEN1*, LEI LUO1, YONG-KUN WANG1, JUN SHANG1, YU ZHANG2, GANG CHEN2 and SHI-KANG LI1 Departments of 1Thoracic and Cardiovascular Surgery and 2Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China Received December 12, 2016; Accepted October 5, 2017 DOI: 10.3892/ijmm.2017.3187 Abstract. Accumulating evidence suggests that the dysregula- adhesion. An lncRNA-miRNA-mRNA regulatory network and tion of long non-coding RNAs (lncRNAs) serves vital roles a protein-protein interaction network were then constructed. in the incidence and progression of lung cancer. However, the Eventually, a prospective lncRNA-miRNA-mRNA regulatory molecular mechanisms of LINC00968, a recently identified network of LINC00968, three miRNAs (miR-9, miR-22 and lncRNA, remain unknown. The objective of present study was miR-4536) and two genes (polo-like kinase 1 and exportin-1) to investigate the role of a prospective lncRNA-miRNA-mRNA was obtained following validation in the Cancer Genome Atlas network regulated by LINC00968 in non-small cell lung database. These results may provide novel insights to support cancer cells. Following the transfection of lentiviruses carrying future research into lncRNA in lung cancer. LINC00968 into A549 cells, the microRNA (miRNA) expres- sion profile of the cells in response to the overexpression of Introduction LINC00968 was detected using an miRNA microarray. Five differentially expressed miRNAs (DEMs) with LINC00968 Lung cancer results in the death of ~1.59 million indi- overexpression were obtained, including miR-9-3p, miR-22-5p, viduals worldwide each year, and is a leading cause of cancer miR-668-3p, miR-3675-3p and miR-4536-3p.
    [Show full text]